PI3K-alpha Inhibitor HS-10352 clinical trials
How each study uses PI3K-alpha Inhibitor HS-10352 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the PI3K-alpha Inhibitor HS-10352 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HS-10352
- 1
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Jiangsu Hansoh Pharmaceutical Co., Ltd. (2) · Henan Cancer Hospital (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses PI3K-alpha Inhibitor HS-10352 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingPhase 1/2Henan Cancer HospitalNCT06788197Written as SHR-A1811+ Fulvestrant+HS-10352How we know
- A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast CancerRecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05504213Written as HS-10352 combined with fulvestrant (Stage 1)How we know
- Phase I Study of the HS-10352 in Patients With Advanced Breast CancerStatus unknownPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT04631835Written as HS-10352How we know